Elisabeth Lorge
Papers
1
Total Citations
74
H-Index
1
About
Dr. Elisabeth Lorge is a leading expert in genetic toxicology, whose work has fundamentally shaped how the safety of chemicals and pharmaceuticals is assessed. Her primary research focuses on the development, validation, and regulatory acceptance of advanced in vitro genotoxicity assays. Dr. Lorge’s most significant contribution is her pioneering role in the multiplexed high content in vitro genotoxicity assay, a sophisticated method that simultaneously measures multiple biomarkers of DNA damage—including p53 activation, γH2AX formation, and mitotic disruption—using flow cytometry. Her landmark 2017 paper on this subject, which has garnered 74 citations, provided the critical interlaboratory evaluation that demonstrated the assay’s robustness and reproducibility. This work has been instrumental in moving the field away from traditional, single-endpoint tests toward more informative, mechanism-based screening. Beyond this, Dr. Lorge has been deeply involved in international harmonization efforts, serving as a key figure in the Organisation for Economic Co-operation and Development (OECD) test guideline development. Her dedication to creating more predictive and human-relevant safety assessments has made her a highly respected voice in regulatory toxicology, directly influencing how industry and agencies evaluate genotoxic risk.
Research Focus
Key Achievements
Top Papers
- 1